Drug recall · July 19, 2023
Bivalirudin for Injection 250 mg recall
Why: Presence of Particulate Matter: Particulate matter identified as fiber.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
Bivalirudin for Injection 250 mg, 10 Single-Dose Vials, Rx Only, Manufactured for: Accord Healthcare, Inc. Durham, NC 27703 Manufactured by: Intas Pharmaceuticals Limited Ahmedabad-382 210, India, NDC 16729-275-67.
- Lots / codes
Lot #: M2212070 Exp. date 08/2024
- Quantity
- 1680 vials
- Company
- Accord Healthcare, Inc., Durham, NC
- Distribution
- Nationwide within the United States
- Initiated
- July 3, 2023 · Voluntary: Firm initiated
- Classified
- July 13, 2023
- Reported
- July 19, 2023
- Ended
- October 17, 2024
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Bivalirudin
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.